Genscript Biotech
Genscript Biotech Corporation, commonly referred to as Genscript, is a leading biotechnology company headquartered in the United States. Founded in 2002, Genscript has established itself as a pioneer in the fields of gene synthesis, peptide synthesis, and antibody development, serving a diverse range of industries including pharmaceuticals, academia, and diagnostics. With major operational regions across North America, Europe, and Asia, Genscript offers a comprehensive suite of services that includes custom gene and protein production, CRISPR gene editing, and molecular biology tools. The company is renowned for its innovative approach and high-quality products, which have positioned it as a trusted partner in the global biotech landscape. Genscript's commitment to advancing scientific research has led to numerous accolades, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Genscript Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genscript Biotech's reported carbon emissions
In 2023, Genscript Biotech reported total carbon emissions of approximately 97,949,660 kg CO2e, comprising about 12,090,920 kg CO2e from Scope 1 and about 85,858,740 kg CO2e from Scope 2 emissions. This marks a significant increase in emissions compared to previous years, with 2019 emissions recorded at approximately 48,371,30 kg CO2e for Scope 1 and about 44,105,720 kg CO2e for Scope 2. Despite the rising emissions, Genscript Biotech has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of documented climate pledges or reduction strategies suggests a need for enhanced commitment to sustainability practices within the biotechnology sector. As the company continues to operate globally from its headquarters in the US, it remains crucial for Genscript to align with industry standards and climate commitments to address the growing concerns surrounding climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,752,700 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 13,782,800 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
